| Methods |
Randomised trial |
| Participants |
171 participants with epithelial ovarian cancer in second or third clinical remission |
| Interventions |
OPT‐821 (n = 86) + polyvalent vaccine conjugate (Globo‐H‐GM2, MUC1‐TN,TF) vs OPT‐821 alone (n = 85) |
| Outcomes |
|
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Low risk |
Randomised trial |
| Allocation concealment (selection bias) |
Low risk |
Randomised allocation |
| Blinding of participants and personnel (performance bias)
All outcomes |
Low risk |
Double‐blinding of participant and investigator |
| Blinding of outcome assessment (detection bias)
All outcomes |
Low risk |
Double‐blinding of participant and investigator |
| Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
All participants analysed for primary endpoint |
| Selective reporting (reporting bias) |
Unclear risk |
Information insufficient to permit judgement of ‘low risk’ or ‘high risk’ |
| Other bias |
Low risk |
No other forms of bias detected |
